Researchers terminate trial examining aliskiren in high-risk patients - Endocrine Today PDF Print
Endocrine Today
Novartis recently announced its decision to halt a trial assessing the safety and efficacy of aliskiren for treatment of hypertension in patients with type 2 diabetes and renal impairment who are at high risk for cardiovascular and renal events,

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.